The coronavirus vaccine developed by AstraZeneca and the University of Oxford is up to 90% effective, according to data from Phase 3 trials.

The results of the trial, which proved the vaccine to be 90% effective in one dosage amount and 62% effective in the other dosage amount resulting in an average efficacy of 70.4%, were announced in a university statement on Monday.